Avicanna announces issuance of U.S. patent
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 11 2025
0mins
Should l Buy ?
Patent Issuance: Avicanna has received a patent from the USPTO for its topical cannabinoid compositions aimed at promoting clear skin, specifically patent No. US 12,343,315 B2.
Formulation and Applications: The patented formulation includes cannabinoids along with antioxidants, anti-microbial, and anti-inflammatory agents, targeting skin conditions such as acne, wrinkles, rosacea, and erythema.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
